Inge Stegeman

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. doi Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands
    Cancer Epidemiol 37:278-83. 2013
  2. pmc Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands
    BMC Gastroenterol 12:73. 2012
  3. doi Cancer risk models and preselection for screening
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, Netherlands
    Cancer Epidemiol 36:461-9. 2012
  4. doi Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands
    Gut 63:466-71. 2014
  5. doi Risk factors for false positive and for false negative test results in screening with fecal occult blood testing
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academical Medical Center, Amsterdam, The Netherlands Department of Research and Development, NDDO Institute for Prevention and Early Diagnostic, Amsterdam, The Netherlands
    Int J Cancer 133:2408-14. 2013
  6. doi Fecal immunochemical testing results and characteristics of colonic lesions
    Sascha C van Doorn
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Endoscopy 47:1011-7. 2015
  7. ncbi [Integrated risk profiling allows prevention and early intervention]
    Inge Stegeman
    Academisch Medisch Centrum, afd Klinische Epidemiologie, Biostatistiek en Bioinformatica, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 154:A1906. 2010
  8. pmc Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
    Inge Stegeman
    Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands Department of Otorhinolaryngology Head and Neck Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 10:e0127194. 2015

Detail Information

Publications8

  1. doi Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands
    Cancer Epidemiol 37:278-83. 2013
    ..75; 95%CI: 1.09-2.82). Elderly screening participants, participants with lower calcium intake, a CRC family history, and smokers are at increased risk of harboring detectable advanced colorectal neoplasia at screening colonoscopy...
  2. pmc Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands
    BMC Gastroenterol 12:73. 2012
    ..We aim to evaluate the participation rate in and yield of a third CRC screening round using FIT...
  3. doi Cancer risk models and preselection for screening
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, Netherlands
    Cancer Epidemiol 36:461-9. 2012
    ..One could argue that it is not so much age that determines the benefits but the risk of developing preclinical and treatable cancer. Cancer risk varies with age but is also affected by other factors...
  4. doi Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands
    Gut 63:466-71. 2014
    ..We explored the use of a risk prediction model in CRC screening...
  5. doi Risk factors for false positive and for false negative test results in screening with fecal occult blood testing
    Inge Stegeman
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academical Medical Center, Amsterdam, The Netherlands Department of Research and Development, NDDO Institute for Prevention and Early Diagnostic, Amsterdam, The Netherlands
    Int J Cancer 133:2408-14. 2013
    ..FIT sensitivity was lower in women. FIT specificity was lower in males, smokers and regular NSAID users. Our results can be used for further evidence based individualization of screening strategies. ..
  6. doi Fecal immunochemical testing results and characteristics of colonic lesions
    Sascha C van Doorn
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Endoscopy 47:1011-7. 2015
    ..The aim of this study was to investigate whether FIT results vary depending on the characteristics of colonic lesions...
  7. ncbi [Integrated risk profiling allows prevention and early intervention]
    Inge Stegeman
    Academisch Medisch Centrum, afd Klinische Epidemiologie, Biostatistiek en Bioinformatica, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 154:A1906. 2010
    ..We demonstrate why the attractive concept of risk profiling needs further assessment to estimate its effectiveness relative to other methods of prevention, population screening and case finding...
  8. pmc Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
    Inge Stegeman
    Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands Department of Otorhinolaryngology Head and Neck Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 10:e0127194. 2015
    ..We aimed to assess, in a quantitative way, benefits and harms of aspirin for primary prevention of both cardiovascular disease and cancer for a general US population between 40 and 85 years of age...